Last reviewed · How we verify
Adjuvant Systemic Therapy
Adjuvant systemic therapy refers to post-operative treatment administered to eliminate residual cancer cells and reduce recurrence risk after surgical resection.
Adjuvant systemic therapy refers to post-operative treatment administered to eliminate residual cancer cells and reduce recurrence risk after surgical resection. Used for Adjuvant treatment of solid tumors post-surgical resection (specific tumor type not specified in available data).
At a glance
| Generic name | Adjuvant Systemic Therapy |
|---|---|
| Also known as | Trastuzumab, T-DM1, Trastuzumab Emtansine, chemotherapy or hormone therapy |
| Sponsor | National Medical Research Radiological Centre of the Ministry of Health of Russia |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Adjuvant therapy is given after primary treatment (surgery) to target micrometastatic disease and improve overall survival. The specific mechanism depends on the modality used—chemotherapy, hormone therapy, targeted therapy, or immunotherapy—each working through distinct pathways to prevent cancer recurrence.
Approved indications
- Adjuvant treatment of solid tumors post-surgical resection (specific tumor type not specified in available data)
Common side effects
Key clinical trials
- HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer (EARLY_PHASE1)
- Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer (PHASE3)
- Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases (PHASE2, PHASE3)
- Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery (PHASE2)
- Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis (PHASE2)
- A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) (PHASE3)
- Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC (PHASE1)
- RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: